Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.

Werner Scheithauer(Comprehensive Cancer Center Vienna), Heinz Ludwig(Wilhelminen Hospital), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Luca Baldini(University of Milan), E Polli(European Institute of Oncology), E. Fritz(Unknown), I. Kührer(St Anna Children's Hospital)
PubMed
April 1, 1989
Cited by 12

Related Papers

International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k